As with many pathogens, most dengue infections are subclinical and therefore unobserved 1 . Coupled with limited understanding of the dynamic behaviour of potential serological markers of infection, this observational problem has wide-ranging implications, including hampering our understanding of individual-and populationlevel correlates of infection and disease risk and how these change over time, between assay interpretations and with cohort design. Here we develop a framework that simultaneously characterizes antibody dynamics and identifies subclinical infections via Bayesian augmentation from detailed cohort data (3,451 individuals with blood draws every 91 days, 143,548 haemagglutination inhibition assay titre measurements) 2,3 . We identify 1,149 infections (95% confidence interval, 1,135-1,163) that were not detected by active surveillance and estimate that 65% of infections are subclinical. After infection, individuals develop a stable set point antibody load after one year that places them within or outside a risk window. Individuals with pre-existing titres of ≤1:40 develop haemorrhagic fever 7.4 (95% confidence interval, 2.5-8.2) times more often than naive individuals compared to 0.0 times for individuals with titres >1:40 (95% confidence interval: 0.0-1.3). Plaque reduction neutralization test titres ≤1:100 were similarly associated with severe disease. Across the population, variability in the size of epidemics results in large-scale temporal changes in infection and disease risk that correlate poorly with age.
infection and identify infection events that were missed by surveillance on the basis of the analysis of longitudinal data from cohort studies. We apply the analysis to data from a school-based cohort study in Thailand (n = 3,451, mean age at recruitment was 9 years old, interquartile range, [8] [9] [10] [11] , in which subjects had blood taken on average every 91 days for up to five years and when illnesses were detected through active surveillance 2 . Surveillance of active fever and school absence of children was conducted from June to mid-November when DENV circulation is concentrated 2 . Haemagglutination inhibition tests were used to measure antibody titres of each serotype in each sample (143,548 haemagglutination inhibition measurements in total). Plaque reduction neutralization test (PRNT) titres were also measured on a subset of 1,771 samples. Haemagglutination inhibition titres correlated closely with PRNT titres (Pearson correlation of 0.91) and with inhibition enzyme-linked immunosorbent assays (ELISAs), although titre values differ between laboratories and between assays [6] [7] [8] [9] .
To track the evolution in the measured antibody titres of an individual ( Fig. 1a ), we placed titres on an adjusted log 2 scale (titres of 1:10 were given a value of 1, 1:20 a value of 2 and so on). There were 274 detected symptomatic DENV infections (Fig. 1b) ; 62 children were hospitalized (23%) and 36 had dengue haemorrhagic fever (DHF) (13%). In cases for which the infecting serotype was known through PCR (79% of cases, Supplementary Table 1) , we observed a sharp rise and subsequent decay in log 2 titres after the onset of symptoms ( Fig. 1c, d ). The mean log 2 titre of the infecting serotype was 0.79 (95% confidence interval, 0.74-0.84) times the log 2 titre of the non-infecting serotype in the three months before onset of symptoms compared to 0.94 (95% confidence interval, 0.93-0.96) times in the six months after the onset of symptoms ( Fig. 1e ). Because 86% of cases with symptomatic infections had detectable titres of at least one serotype before infection, the higher antibody titre of non-infecting serotypes probably captures responses to prior infections 10 .
We reconstructed the antibody trajectories of each individual by assuming that infection leads to an increase in titres that subsequently decays exponentially 11 . We also explored biphasic responses (Extended Data Fig. 1 ). We allow for variability in antibody kinetics across individuals and infections, and for differential rises for the infecting versus the non-infecting serotypes for primary infections but undifferentiated responses for subsequent infections. We use data augmentation techniques to impute undetected infections (subclinical infections during active surveillance or unknown symptom status outside the surveillance windows) and to identify the serotype of undetected primary infections 3 . Instead of relying on fixed cut-offs to identify infections, data augmentation allows us to incorporate uncertainty in the existence, timing and serotype of unobserved infection events and therefore Letter reSeArCH we can probabilistically assess whether differences in measured titres are due to infections or assay variability.
We find that after post-primary infections, there is a mean increase of 5.8 (95% confidence interval, 5.6-5.9) in log 2 titres across serotypes, which decreases by 76% after one year. For primary infections (that is, individuals without detectable titres before infection), the mean increase in log 2 titre is 7.6 (95% confidence interval, 7.4-7.8) for the infecting serotype and 6.6 for non-infecting serotypes (95% confidence interval, 6.4-6.7). The similarity in titres of infecting and non-infecting serotypes coupled with assay variability suggests that in a clinical setting individual haemagglutination inhibition measurements cannot reliably determine the infecting serotype. We find that titres largely stabilize one year after infection to a set point (the 'set-point antibody load'; Fig. 1d ). There is substantial variability between infections: the interquartile range of the increase in log 2 titre one year after infection is 0.7-2.2 across all infections (Extended Data Fig. 2a ). We find that even after accounting for historic infection status, measured DENV2 titres are systematically lower than other serotypes (0.85 lower than DENV1; Extended Data Fig. 2b and Supplementary Table 2 ), which could indicate technical considerations of the DENV2 assay or inherent differences in immune responses to DENV2. We estimate the measurement error in the haemagglutination inhibition assay (that is, the standard deviation in any reading) to be 0.49 (95% confidence interval, 0.49-0.50), which is similar to the empirically estimated standard deviation using repeated testing on the same serum and 2.6 times the error estimates of the PRNT 12 (Extended Data Fig. 2c ). Despite the variability in individual readings, because we use many readings from four serotypes for each participant and titres appear to behave in a stable and predictable manner, we can nevertheless make robust inferences when considering the ensemble of the measurements.
We probabilistically identify 1,149 undetected infections (95% range across model iterations, 1,135-1,163), of which 507 (494-520) occurred during active surveillance periods and were therefore subclinical ( Fig. 1b) . Overall, we estimate that 35% of infections are symptomatic (95% confidence interval, 34-36%). The temporal distribution of subclinical infections was correlated with that of symptomatic infections (Pearson correlation of 0.78, 95% confidence interval, 0.70-0.84). Using augmented primary infections for cases in which we could confidently assign the infecting serotype (same serotype implicated by >50% of iterations), we find that 34% of undetected primary infections (and 39% of subclinicial primary infections) were due to DENV4, compared to only 3% of all symptomatic infections (none of which were primary infections; Extended Data Fig. 3a, b ). We find consistent results using a more stringent cutoff to assign the infecting serotype (Extended Data Fig. 3c ). These findings are consistent with a reduced risk of disease from DENV4 compared to other serotypes resulting in a mostly silent DENV4 epidemic. This is supported by a phylogenetic analysis that found that DENV4 was widespread in Thailand throughout this period (see supplementary figure 4 of Salje et al. 13 ). This suggests that the serotype distributions from hospital-based or community-based surveillance may not be representative of infections in the population and supports previous evidence that the transmissibility of a serotype can be delinked from the propensity to cause symptomatic and/or severe disease 14, 15 . Furthermore, these results indicate that factors that contribute to transmission potential (for example, viral replication, peak titres or infection length) are not predictive of adverse outcomes 16 .
We find that the underlying probability of infection and the probability of developing disease are strongly linked to the mean antibody titre at the time of exposure. Overall, an individual's annual risk of infection was 17%, varying from 21% for individuals with mean measured log 2 titres of <2, to 16% for those with log 2 titres of 2-3 and 11% for those with log 2 titres of >3 ( Fig. 2a ). Using logistic regression, we find that for log 2 titres of >2, each unit increase in log 2 titres is associated with a 0.71× relative risk of infection (95% confidence interval, 0.67-0.76). The periods of active surveillance are in pink (5.5 months per year). c, Model fit (lines) and observed (dots) titres pre-and post-infection for primary infections (infecting serotype in blue, non-infecting serotypes in red) and subsequent infections (green). d, Mean difference between the observed log 2 titres at different time points after infection with those at one year after infection for all augmented and observed infections (average of 1,421 total infections across 100 reconstructed datasets) with 95% confidence intervals. Ref., reference time point. e, Titre ratio of the infecting to the mean of the three non-infecting serotypes before and after symptom onset with 95% confidence intervals for the 217 individuals with symptomatic infections for which the infecting serotype was detected (n = 3,366 total titre measurements).
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The annual probability of having a symptomatic infection varies from 6.4% (95% confidence interval, 4.9-8.4%) for primary infections to 8.4% (95% confidence interval, 7.8-9.1%) for individuals with preexisting log 2 titres ≤3 (≤1:40 on a linear scale) and 4.0% (95% confidence interval, 3.0-5.0%) for those with log 2 titres >3 (Fig. 2b ). The annual probability of being hospitalized during a primary infection was 1.2% (95% confidence interval, 0.5-2.1%), compared to 2.4% (95% confidence interval, 2.1-2.7%) during a subsequent infection for those with pre-existing log 2 titres ≤3 and 0.3% for those with log 2 titres >3 (95% confidence interval, 0.09-0.6%; Fig. 2c ). Even more pronounced was the risk for developing DHF, which ranged from 0.2% (95% confidence interval, 0.0-0.6%) for primary infections to 1.5% (95% confidence interval, 1.3-1.7%) for subsequent infections in those patients with log 2 titres ≤3 and 0.0% for log 2 titres >3 (95% confidence interval, 0.0-0.4%; Fig. 2d ). Within this study population, an average of 54% of the population had detectable log 2 titres of ≤3 at any point in time. Time-varying Cox proportional hazards models that specifically account for the dependence of titre observations within individuals gave similar results 17 (Extended Data Fig. 4 ). Using log 2 titres to probabilistically identify the cohort participants with detectable titres that will develop DHF has an area under the curve (AUC) value of 0.66 (Extended Data Fig. 5 ).
When considering only infected individuals, we observe no difference in the probability of subclinical infection by titre; however, the probability of hospitalization and DHF remains the highest in those with pre-existing log 2 titres of ≤3 (Extended Data Fig. 6a -c). Only one individual with pre-infection log 2 titres >3 developed DHF during surveillance compared to 146 who did not, but who had titres at infection within the same range. This suggests that in the event that infection does take place, antibodies are not protective against developing symptoms as such, but conversely, are associated with the development of severe disease. We observe no difference in the risk of disease given infection across years ( Supplementary Table 3 ) or age ( Supplementary  Table 4 ). Other studies are needed to investigate whether younger age groups than those included here nevertheless have an increased risk. PRNTs form the basis of current discussions on immune correlates. Among those infected, individuals with detectable PRNT log 2 titres of ≤4.5 (equivalent to approximately ≤1:100) have a 7.5 times (95% confidence interval, 2.4-11.6) higher risk of DHF compared to previously naive individuals, compared to 0.0 times for those with higher titres (Extended Data Fig. 6d-f ). Cross-reactive titres that result from exposure to non-DENV flaviviruses such as Japanese encephalitis and Zika may be included in these risk estimates.
Our findings suggest that after infection set-point antibody loads appear to be important for the determination of individual infection and disease risk. After infection, we estimate the daily probability of a subsequent infection and the development of DHF disease as a function of titre dynamics. We demonstrate that the probability of both infection and disease stabilizes after one year ( Fig. 3 ). On the basis of the observation in Fig. 2 that individuals with detectable titres of ≤3 had an increased risk of infection and disease, we explored the temporal evolution of risk following infection for those with set-point antibody loads (that is, the titre at one year following infection) above and below this threshold. At one year, we observe a 2.1 times higher risk of infection (irrespective of disease outcome) for those with set-point antibody loads of ≤3 compared to those with greater antibody loads and an 8.9 times higher risk of infection that leads to DHF. Overall, we find that three years after infection, 34% of individuals with set-point antibody loads of ≤3 suffer a subsequent infection, irrespective of severity (95% confidence interval, 33-35%) compared to 23% for those with greater loads (95% confidence interval, 20-26%). After this delay, 3.5% of individuals with set-point loads of ≤3 develop DHF disease (2.4-4.4%) compared to none in those with higher loads. The apparent stability of set-point antibody loads points to an ability to assess the long-term risk of an individual.
Our findings are consistent with low titres generated by some candidate vaccines in previously naive individuals, 'priming' individuals for severe disease upon their first exposure 18 . A hypothesis that is supported by previous evidence that primary infections in infants with maternal antibodies and secondary infections in older individuals are associated with severe disease 19, 20 . Furthermore, a Nicaraguan study found elevated risk of severe disease for those with low inhibition ELISA titres at prior annual blood draws 9 . Previously naive individuals given the dengvaxia vaccine had mean PRNT titres within our risk window 21 (Fig. 4d ). Further work is required to understand whether immunity acquired from vaccination and natural infection are qualitatively similar and whether the risk window described here is relevant for vaccine recipients. T cell immunity, which is not captured by these assays, might compensate for antibody titres in this window. Vaccine studies should carefully assess the criteria used to define seroconversion, and how titres correlate with disease risk over time. Our work suggests that previously used criteria (PRNT titre >1:10) do not adequately correlate with reduction in disease risk and suggest that haemagglutination inhibition titres >1:40 or PRNT titres of >1:100 may provide a starting point for any vaccine in identifying a targeted neutralizing antibody response. Placebo data from the dengvaxia vaccine trials also suggests higher PRNT titres are linked to protection 22 . The targeted vaccination of individuals that have pre-existing antibody titres within our zone may be a viable approach to minimize the public health burden from dengue by moving individuals away from the risk window ( Fig. 4d ). Even in an endemic setting such as our cohort, there is considerable temporal variability in the serological status of 9-year-old individuals (Extended Data Fig. 7 ), suggesting that the current WHO guidance surrounding dengvaxia or similar guidance that Letter reSeArCH is based on serostatus at vaccination will have to carefully consider this variation or specifically screen individuals.
Our approach allows us to consider wider problems concerning drivers of dengue epidemiology. The assumption that population-wide immunity varies across time and dictates multi-annual dynamics of dengue pervades the literature and dominates current hypotheses about what drives large outbreaks of dengue in particular settings 18, [23] [24] [25] [26] . More generally, the idea that temporally varying population immunity drives temporal dynamics of pathogens pervades infectious disease epidemiology [27] [28] [29] . However, quantitative evidence that any population varies in dengue immune status over time is mostly unavailable, as is a link between the immune status of a population and the risk of epidemics in empirical data. Here, although we have only a short time series, we show that underlying the heterogeneity in the size of annual epidemics indicates that the risk of having titres within the risk zone for different birth cohorts is more correlated with the epidemic time point ( Fig. 4a , mean correlation of 0.70) than with age ( Fig. 4b , mean correlation of 0.23). Although both the probability of being naive and having log 2 titres above the risk zone correlated with age, strong birth-cohort effects also exist (Extended Data Fig. 7 ). For example, among 9-year olds, we observe up to a twofold difference in the probability of being naive, depending on the year of the study.
Finally, our results can guide the design of cohort studies aiming to characterize transmission. Studies typically use a fourfold rise in titres against any serotype as evidence of infection, regardless of the timing of sample collection. Using our titre trajectories, we find that if blood draws are every 90 days, a fourfold cutoff point on measured titres has a specificity of >99% and a sensitivity of 87% ( Fig. 4c and Extended Data Fig. 8 ). The sensitivity is reduced to 77% when blood is taken every six months and 62% when blood is taken annually, although it may be higher in seasonal settings when samples are taken at the end of the season. Using an alternative approach that uses the mean titre across the four serotypes and a 1.6-fold cutoff point, the sensitivity of the assay improves to 96% when samples are taken every six months and to 90% for annual bleeds (specificity >95%; Extended Data Fig. 9 ). We provide the optimal cutoff point and estimated sensitivity for these approaches and a theoretical estimate in which titres are on a continuous scale (such as PRNT) and for which a minimum specificity of >99% is required (Extended Data Fig. 9 ).
We demonstrate through simulation that our framework can recover the true number of subclinical infections and parameters when only 30% of infections are symptomatic (Supplementary Table 5 ). Our approach is also robust to a scenario in which there are differential rises in titres for symptomatic and non-symptomatic infections ( Supplementary Table 6 ) and in which we incorporate school-specific force of infection parameters ( Supplementary Table 7 ). In addition, we find that the timing (Extended Data Fig. 10a ) and the serotype (Extended Data Fig. 10b ) of undetected infections cluster in the same locations as symptomatic infections. This provides strong support for our modelling framework by suggesting that the model can correctly identify spatiotemporal clustering of otherwise undetected infections. These findings also support focal transmission, irrespective of disease outcome 13, 30, 31 . The approach presented here will be applicable across disease systems for which longitudinal titre data exists, allowing a wide range of insights into fundamental questions of disease ecology and risk. Data are from the average of 1,420 infections across 100 reconstructed datasets. a, c, The probability of survival from subsequent infection (irrespective of disease outcome (a) and for those that led to DHF (c)) as calculated from Kaplan-Meier curves for those infections with set-point antibody titres of ≤3 (red) and >3 (blue) with 95% confidence intervals. The annualized probability of a subsequent infection (irrespective of disease outcome (b) and for those that led to DHF (d)) at different time points following infection for those infections with set-point antibody titres of ≤3 (red) and >3 (blue).
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MEthodS Cohort study design. Individuals attending 12 different schools in the Kamphaeng Phet district, a rural region of Northern Thailand were recruited into a dengue cohort study that ran between 1998 and 2003 as previously described 32 . All individuals were between 7 and 13 years old. Blood samples were taken four times a year (in January, June, August and November) with an average of 91 days between blood draws. In addition, from the start of June to mid-November each year, active surveillance was conducted through school-based surveillance. Children who missed school due to febrile illness had additional acute and convalescent blood draws. Dengue infection was confirmed using RT-PCR on the acute sample, with the infecting serotype also recorded or through antibody detection (IgM ELISA values >40 or haemagglutination inhibition test increases of over four times between acute and convalescent blood draws), in which case the infecting serotype was not known. The date of symptom onset, whether or not the child was hospitalized and whether or not they developed DHF was also recorded. Note that the cohort study was conducted before 2009, when the WHO provided new guidance for the characterization of different levels of dengue severity. Antibody measurements. For each blood draw of each individual, antibody titres for DENV1, DENV2, DENV3 and DENV4 were measured using a haemagglutination inhibition assay. The following twofold dilutions were used: 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, 1:1,280 and 1:2,560. We translated each titre onto a log 2 scale such that 1:10 was given a value of 1, 1:20 of value of 2 and so on. Undetectable titres (those with a titre of <1:10) were given a value of 0. For a subset of 800 individuals, 1,771 samples were also tested using PRNTs. These samples were either paired samples from individuals with symptomatic, confirmed infection with one sample taken from a time point before symptom onset and one sample after symptom onset (n = 75 pairs) or randomly chosen sequential blood samples from individuals without a detected symptomatic infection between the blood draws. Characterizing how titres change after symptomatic infection. We wanted to understand how titres to both the infecting serotype and to non-infecting serotypes changed over time before and after symptom onset. For all individuals that experienced a symptomatic illness for which the infecting serotype was identified, we identify all titre measurements within each 10-day window from 100 days before symptom onset to 600 days after symptom onset. For each window, we calculated the mean titre of the infecting serotype and the average of the mean titres of the other three serotypes across all individuals that had a blood draw within that window. Modelling the dynamics of dengue antibody titres. Previous studies on malaria have used hidden Markov models to include undetected infections in estimates of the transmission intensity using presence/absence of specific antibodies in longitudinal data 33 . Although these efforts were able to improve estimates of the infection strength within a community compared to using symptomatic individuals, they did not incorporate the changing dynamics of antibody titres over time. By specifically including titre dynamics, we can help to understand a wide range of issues, including assay error, measures of protection and risk and cohort design. Notation. We consider an individual i. We denote the number of times the individual was infected before time t. Each dengue infection of individual i is labelled by the index ψ = … n t 1, , ( ) i I . We denote as τ ψ i I , the time of infection number ψ of individual i and s i,ψ is the infecting serotype of infection number ψ of individual i. The history of infection (that is, the timing and serotype of all infections since birth) of individual i up to time t is labelled H i (t). We denote as N i A the total number of times the individual had blood taken during the study. Each blood draw of individual i is labelled by the index π = … N 1, , i A . We denote as τ π i A , the time of blood draw π for individual i. We denote as A i,s,π the true antibody titre (see 'Measurement model') and π * A i s , , is the measured antibody titre for individual i for serotype s at blood draw π. Λ i (t) represents the cumulative infection strength exerted on individual i before time t. The parameter vector is denoted by θ.
Hierarchical structure of the model. We can break down the probability of a measured antibody titre into three components: 
The first part represents the 'measurement model' , the second part the 'antibody dynamics model' and the third part the 'infection model' . Measurement model. We model the underlying antibody levels on a continuous scale, however, the haemagglutination inhibition assay is a discrete assay, such that in a situation of no measurement error or systematic biases, a true antibody titre between any two dilutions would be measured as the lower of the two dilutions.
So, for example, a true titre of 2.7 would be measured as 2 (assuming there are dilutions performed at 0, 1, 2, 3, …). In addition, a measurement error is also likely to exist and there may be underlying differences between serotypes (that is, serotypespecific biases) in the assay that will impact all measurements of antibodies against a particular serotype. We consider a 'true titre' to represent the underlying (but unmeasured) titre on a continuous scale. A 'measured titre' is the value that is actually measured by the assay. Conditional on the history of infection of an individual, we assume independence between the measurements of the different serotypes. This seems a reasonable assumption as assays are performed separately for each serotype. The probability of the measured titres
is:
, ,
where f(u) is the density for a normal distribution with mean A i,s,k + χ s and a standard deviation parameter (σ), where
Antibody dynamics model. If an individual i was never infected by dengue, we assume that they will have titres of 0 against the four serotypes (this assumes that any maternal antibodies have disappeared and there is no impact of infections by other flaviviruses). At each time point that the individual becomes infected, their antibody titres will increase. We assume that this increase can be broken down into a permanent increase (representing antibodies that will continue to circulate, long after the infection has passed) and a temporary increase (representing the short-lived antibodies generated upon infection). The permanent rise in titres (Q i,s (ψ)), for serotype s from infection number ψ in individual i is modelled as:
where ω i,ψ is a random effect that is gamma-distributed with mean parameter ω m and variance parameter ω v and K(ψ, s) allows a differential antibody response for each serotype for primary infections: K(ψ, s) = η if it is a primary infection (that is, ψ = 1) and s is the infecting serotype; K(ψ, s) = 1 otherwise. We assume that temporary antibody responses will decay exponentially over time:
is a random effect that captures the instantaneous rise in temporary antibody titres following the most recent infection (infection n t ( ) i I ) before time t that comes from a gamma distribution with mean parameter γ m and variance parameter γ v ; δ ψ=
is the rate of decay of the temporary antibodies and comes from a gamma distribution with mean parameter δ m and variance parameter δ v . As with the permanent rise in titres, ψ = K n t s ( (), ) i I allows differential antibody responses for primary infections: K(ψ, s) = η if it is a primary infection (that is, ψ = 1) and s is the infecting serotype; K(ψ, s) = 1 otherwise. Additional work is needed to understand whether alternative functional forms for the rise and decay in antibody titres may further refine how antibodies behave following infection.
Under these assumptions and an additional linearity assumption that the temporary and permanent rises are additive, antibody titres at blood draw k for serotype s in individual i is: 
Infection history model. We first assume that both the number of infections and the timing of infections are known. This assumption will subsequently be relaxed. We assume that each individual can get infected up to four times (once by each serotype). The history of infection of an individual depends on seasonality in dengue transmission and differences in infection intensity across years. For a particular time t, the force of infection is assumed to be:
where λ is a parameter that represents the mean daily force of infection in 1998
(the first year of the study) and | | β t is the mean force of infection in year |t| compared to the force of infection in 1998.
For an individual i, the contribution to the likelihood for periods before any infection, the probability of their infection history can be broken down into periods of infection and periods without infection. Individuals only contribute to the likelihood during their time in the study.
For each infection that occurs at time t, the contribution to the likelihood is:
For each individual, each day during which no infection occurs, the contribution to the likelihood with respect to serotype s is exp(−λ(t)) where more than 90 days have passed since an infection by any serotype and the individual has not previously been infected by serotype s or is 0 otherwise, including periods when the individual is not part of the study
The presence of the 90-day window during which no infection can take place avoids there being more than one infection event between two blood draws. This period is substantially shorter than the estimated period of cross-protection between serotypes of two years 34 .
In the context of full observation, the probability of the history of infection for individual i can be given as: Situation of imperfect observation. In practice, we do not know the infection history of all individuals. Many infections will have occurred before individuals entered the study. In addition, there are likely to be many subclinical infections that would not have been detected through active surveillance. In addition, active surveillance only operated for 5.5 months of every year. Infections outside these periods would also have been missed (irrespective of symptoms).
For the infection history of individuals before they enter into the study, we estimate a baseline titre (A i,s (t 0 )) that represents the titre for serotype s one year before the first blood draw. As we assume linearity, such that the temporary and permanent titres of successive historic infections sum up to give the titre at a moment in time, this estimated baseline titre allows us to incorporate the impact of historic infection events up to one year before enrolment but means that we do not need to infer infection events before that time. Individuals that are naive at baseline (defined as those with no measured titres for any serotype at the first blood draw) are given a baseline titre of 0. For an individual with no infection events during the study period, A i,s (t) = A i,s (t 0 ) for all t.
In the context of full observation during the study period, each individual would have the serotype and time from each infection, {s i,ψ , τ i,ψ }, known. For undetected infections or detected infections for which the infecting serotype is unknown (such as when symptomatic infections are only detected through IgM ELISA and therefore the serotype is unknown), we can use a Bayesian data augmentation framework. In this framework, the incompletely observed ( ) is the titre model outlined above and θ P ( ) gives the prior distribution of the parameters. The observation model makes sure that the augmented datasets are consistent with the observed data by having a value of 1 (if consistent) or 0 (if inconsistent). Consistent augmented data have the following characteristics: (1) no individual is infected during the study period by the same serotype more than once; (2) no individual is infected more than once during a 90-day period. Note that, as DENV titre responses to non-DENV flaviviruses, such as Zika and Japanese encephalitis, are likely to be smaller those to DENV infections, such exposures are unlikely to be detected by our model and incorporated as a measurement uncertainty instead.
For all detected (symptomatic) infections, we only detect the date of symptom onset and not the date of infection. To obtain the day of infection for symptomatic cases, we subtract a fixed period of seven days from the day of symptom onset, representing the median incubation period for dengue 35 . Titres may also not rise on the day of symptom onset (due to recall bias in when symptoms started or individual level variability). For symptomatic infections, we approximate the true, unobserved day of titre increase using augmentation, for which we define consistent augmented data for which the day of titre increase is within ten days of the reported date of symptom onset. For augmented (undetected) infections, we assume that the day of titre rise following infection always occurs 11 days after the day of infection, which represents an approximate estimate of the time between infection and day of titre increase: calculated as the sum of the median incubation period for dengue (seven days) and the median time between symptom onset and titre increase for the detected infections (four days).
This cohort used a rolling recruitment approach, which maintained an approximately constant-sized population and constitutes an important strength compared to cohorts for which the size may be strongly affected by participant dropout. As individuals only contributed to the likelihood for their period of inclusion in the cohort and dropout is not expected to depend on the history of infection, we do not expect that the turnover of participants in the cohort will bias parameter estimates. This was demonstrated in a simulation study in which we were able to recover the true parameters for a simulated cohort with a similar design (see 'Evaluation of the model using simulated data').
We use a log-normal distribution with a log-mean of 0 and log-variance of 1 for the parameters: mean and variance in the permanent rise in log 2 titres (ω m, ω v ), mean and variance in the temporary rise in log 2 titres (γ m , γ v ), mean and variance in the decay in log 2 titres per day (δ m , δ v ), difference in rise for infecting compared to non-infecting serotype (primary infection only) (η), measurement error (σ), DENV2-4 bias (χ 2, χ 3, χ 4 ), daily infection strength in 1998 per serotype (λ), relative infection strengths versus 1998 for 1997 (β 0 ) and 1999-2002 (β 2 -β 5 ) and the two seasonality parameters (δ and ζ). Estimation using MCMC. We develop a MCMC approach to explore the joint posterior distribution of parameters and the augmented data with the following steps:
(1) Metropolis-Hastings update for the model parameters θ in turn with the updates performed on a logarithmic scale. The step size of the proposals was adjusted to obtain an acceptance probability of 20-30%. As the vast majority of infections are undetected, when updating the six parameters that determine the rise and decay of antibodies (namely ω m, ω v , δ m , δ v , γ m , γ v ), we calculate the likelihood using only the titres from one month before and one year after the symptomatic (and therefore detected) infections. This approach assumes that the rise and fall in titres from all infections come from the same distributions, irrespective of symptom status. More work is needed to understand whether, depending on whether or not an infection leads to symptoms, the titre dynamics following that infection change.
(2) For the symptomatic cases, because the day of titre increase may not fall exactly on the recorded day of symptom onset, we use an independence sampler to update the day of titre increase. At each iteration, the day of the titre increase was updated for 100 randomly chosen symptomatic infections. Candidate values were chosen using a uniform distribution between 10 days before and 10 days after the recorded date of symptom onset.
(3) Independence sampler for the identity of the infecting serotype for the 62 symptomatic infections for which the serotype was not identified. At each iteration, the serotype for each of these infections is updated with equal probability across the four serotypes.
(4) Independence sampler for the identity of the infecting serotype for the undetected infections. At each iteration, the serotype of 500 randomly chosen undetected infections is updated with equal probability across the four serotypes.
(5) Independence sampler for the dates of titre increase for undetected infections. At each iteration, the day of infection is updated for 1,000 randomly chosen undetected infections. For each infection, the proposal is a uniform distribution between one year before entry into the study and the day of the final blood draw.
(6) Independence sampler for the baseline titres for each individual. At each iteration, the baseline titre for one serotype is updated for 1,000 randomly chosen Letter reSeArCH individuals. The proposal distribution is a random uniform distribution between 0 and 10. All individuals that are naive at baseline (that is, those with no titres to any serotype at the first blood draw) are forced to have a baseline titre to 0 for all four serotypes. (7) Reversible-jump MCMC to add/remove unobserved infection events. As H i (t j ) is unobserved, we use a Bayesian data augmentation approach that treats it as a nuisance parameter. Rather than attempting to definitively identify whether an infection occurred or not, these approaches allow us to incorporate the uncertainty of the presence and timing of these events. We use a reversible-jump MCMC model to add and remove infection events. Each step to add undetected infections proceeds as follows:
(i) Randomly draw individual.
(ii) Draw a candidate date for the infection event using a uniform distribution from one year before their first blood draw to the day of their final blood draw.
(iii) Draw a candidate serotype of infection with the probability of each serotype being 0.25.
(iv) Update the number, date and serotype of infections for that individual.
For the removal of undetected infections, we use a similar approach: (i) Randomly draw individual.
(ii) If that individual has undetected infections, randomly select one of their infections with equal probability (if they have no infections move to the next individual).
(iii) Update the number, date and serotype of infections for that individual by removing that infection. Evaluation of the model using simulated data. In order to evaluate the ability of the model to accurately estimate the parameters in a scenario when only a minority of infections are observed, we use the same modelling framework on a random subset of 1,000 individuals from the study with subsequent changes in titres. We include the actual start date and the end date for these individuals (that is, when they entered and left the cohort). We simulate infections in these individuals based on known parameters. We then randomly 'unobserve' 70% of infections to reflect undetected infections. We then estimate the parameters using our framework and compare them to the underlying true parameters. Sensitivity analysis using school-specific infection strength parameters. The infection strength exerted on individuals may differ across schools, resulting in nonindependence between individuals attending the same school. To assess the impact of any such correlation on our parameters, we performed a sensitivity analysis in which we included a separate force of infection parameter for each school. In this model the force of infection exerted on an individual that attends school (sch) is:
where λ is a parameter that represents the mean daily force of infection in 1998 in school 1, | | β t is the mean force of infection in year |t| as compared to that in 1998 and | | β sch is the mean force of infection for school sch compared to school 1. Alternative functional forms for the decay in titres. Alternative functional forms for the decay in antibody titres exist. In particular, biphasic models that model both short-term and longer-term antibody decay with different exponential decay rates have been shown to work well in other systems, such as malaria 36 . The biphiasic form is captured by:
where θ 1 , θ 2 , θ 3 and θ 4 capture the decay of the titres. To explore whether this biphasic form may further refine how antibodies behave following infection, we fitted both exponential decay and biphasic models to the observed infections using the observed titres following detected PCR-confirmed infections and the dates of symptom onset. We found largely consistent results in the two models (Extended Data Fig. 1 ). As exponential decay is the more parsimonious model, we retained this form for the final analysis. Nevertheless, structural uncertainty in the model used for the analysis remains, which will not be represented within the confidence intervals for the parameters.
Estimation of impact on titres on infection and disease. We use the augmented times and serotypes of infection from 100 model iterations to reconstruct the antibody titre trajectories for each individual. For each augmented dataset, we extract the mean titre across all four serotypes for each day and whether they got infected the following day or not. Person time for individuals who were considered not susceptible (that is, had been infected in the prior 90 days) was excluded. To explore the relationship between mean titre and the probability of infection, we conducted logistic regression for which a polynomial spline of order 2 for the mean titre was used (determined as the optimal model through comparison of different polynomial models using the Akaike information criterion (AIC)). To account for sampling uncertainty, in each reconstructed dataset, we use a bootstrap approach to sample all individuals with replacement and then re-perform the logistic regression each time. We present the mean and 95% confidence intervals from the resulting distribution of the logistic model estimates of the probability of infection for each titre obtained from across the model iterations. We explore the relationship between mean titre and the probability of having different disease outcomes. We consider three different outcomes: symptomatic infection (irrespective of severity), hospitalization and DHF. We only consider titres during the active surveillance windows and whether or not individuals had an infection the following day that led to the outcome of interest. For each outcome, we conduct logistic regression in which we use a polynomial spline of order 2 for the mean titre (consistently determined as the optimal model through comparison of different polynomial models using AIC). We use a bootstrap approach to sample all individuals with replacement and then re-perform the logistic regression each time and identified the mean and 95% confidence intervals from the resultant distribution for the estimates of the probability of having an infection that led to the outcome of interest for each titre obtained from across the model iterations.
For those individuals that became infected during the active surveillance windows, we fit logistic models to the mean titres and whether or not the disease outcome occurred. We looked at three outcomes: any symptomatic illness, hospitalization and DHF. For each of the three outcomes, we compare an interceptonly model with models with a polynomial spline up to order 2. To account for sampling uncertainty, in each reconstructed dataset, we use a bootstrap approach to sample all individuals who had an infection during the surveillance windows with replacement and then re-perform the logistic regression each time. We present the mean and 95% confidence intervals from the resultant distribution of the logistic model estimates of the probability of infection for each titre obtained from across the model iterations.
PRNT titres are available for a subset of 1,771 blood draws. For those that became infected during the active surveillance windows and PRNT titres are available in the six-month window before infection, we fit logistic models to these mean PRNT titres from that six-month time frame and whether or not the disease outcome occurred. We looked at three outcomes: any symptomatic illness, hospitalization and DHF. For each of the three outcomes of interest, we compare an intercept only model with models with a polynomial spline up to order 2. To account for sampling uncertainty, in each reconstructed dataset, we use a bootstrap approach to sample all individuals who had an infection during the surveillance windows with replacement and then re-perform the logistic regression each time.
To account for the fact that individuals and serum samples may not have been completely selected at random for PRNT testing (for example, preferential testing of those with symptomatic disease), we adjusted our estimate for the probability of sampling conditional on the outcome of interest. From the logistic regression described above, we can extract the probability of the outcome of interest given a particular PRNT titre and that a PRNT was conducted. Using Bayes rule we can write down: as the PRNT titre (or the haemagglutination inhibition titre) was not taken into account in the selection process for choosing whether or not a PRNT was done, this becomes:
As we are interested in P(PRNT done | outcome), we can reorder this equation to:
We therefore multiply our logistic model outcomes by the following adjustment factor: = P P adjustment factor (PRNT done) (PRNT done outcome) P(PRNT done) is calculated as the proportion of all infection events for which a PRNT was conducted in the prior 6 months from the infection and P(PRNT done | outcome) is calculated as the proportion with the outcome of interest for which PRNTs were conducted in the prior 6 months. We present the mean and 95% confidence intervals from the resultant distribution of the logistic model estimates of the probability of infection for each titre obtained from across the model iterations.
We used a logistic regression approach to explore the impact of year of infection and the age at the time of infection. To explore the impact of year, we take each augmented dataset in turn and sample all the individuals with replacement to incorporate sampling uncertainty. We then regress the year of infection (as a categorical variable) on whether the outcome Y i,t occurred:
where Year i,t is the year (1998, 1999, 2000, 2001 or 2002) within which day t occurred for individual i. We conducted separate regressions for which the outcome was an infection event (irrespective of whether the infection led to symptoms), symptomatic infection events (irrespective of disease severity), hospitalization and development of DHF. For the last three models, we only considered data during the active surveillance windows, as we do not know the symptom status of infections outside these windows. To explore the impact of age, we dichotomized the age of individuals as being less than or greater than 9 (the Sanofi-Pasteur vaccine is not recommended for individuals under 9). We then performed the regression:
where separate models for the same four outcomes, Y i,t , were performed. Finally, we built multivariable models that also accounted for mean titre using a polynomial of order 2:
Impact of titre on outcome using Cox proportional hazard models. In the context of small probabilities of an event occurring and short time intervals between readings, logistic regression will give consistent results with those obtained from Cox proportional hazards models that specifically takes the non-independence of titre observations from the same individuals into account 17 . To demonstrate the consistency of the two approaches we estimate the impact of titre on our four outcomes (infection, symptomatic infection, hospitalized infection and DHF infection) using a time-varying Cox proportional hazards model, specifically incorporating clustering of observations by individual 37 . We used 100 augmented datasets. For each augmented dataset, we extract the mean titre across all four serotypes for each day and whether they got the outcome of interest the following day or not. For the disease-specific outcomes (any symptomatic disease, hospitalized infection and DHF infection), we only used time points during the surveillance windows. We then calculated the impact of the mean titre (polynomial of order 2) on the relative hazard of infection, incorporating a clustering ID per individual using the survival package in R 37 . We then calculate the mean effect of titre on the outcome of interest by averaging the estimates across the reconstructed datasets. To compare our results using logistic regression, we multiply the annualized estimate of a titre x on the risk of the outcome (calculated as 1 − exp(−365x)) by the estimated baseline hazard for those cases with a measured titre of 0 (calculated as the proportion of infections in time points with a measured titre of 0). We find that the results are almost identical (Extended Data Fig. 6 ). As the logistic model approaches allow us to directly estimate the underlying probability of the outcome, it is preferred. Survival analysis. Annualized probability of infection using titre data only. Over 100 reconstructed datasets, we initially identify all individuals who experienced an infection (irrespective of disease severity). We then identify the set-point antibody load for that infection as the mean titre one year following infection as predicted by our model. Individuals were divided into two groups, those with a set-point antibody load ≤3 and those with a load >3. For each individual in each titre group, we use the logistic model described in 'Estimation of impact on titres on infection and disease' to predict the daily probability of a subsequent infection based on the mean titres each day following the initial infection. We also calculated the daily probability of experiencing an infection that leads to DHF. We annualize the predicted probabilities of subsequent infection by using the conversion 1 − exp(−365x) where x is the daily probability of infection. We present the mean annualized probabilities across all individuals and over all the reconstructed datasets. Kaplan-Meier analysis. For individuals who experienced an infection, we calculate Kaplan-Meier survival curves for experiencing a subsequent infection (both irrespective of disease outcome and for DHF only). Over 100 reconstructed datasets, we identify all individuals who experienced an infection event. We then identify the set-point antibody load for that infection as the mean titre one year following infection as predicted by our model. Individuals were divided into two groups, those with a set-point antibody load ≤3 and those with a load >3. To incorporate sampling uncertainty, we resample all individuals with replacement. For each group, we then calculate Kaplan-Meier survival curves. We present the mean and 2.5 and 97.5 quantiles from the resulting distribution.
Prediction of DHF outcome using mean titre. We assess the ability of our logistic model to discriminate between those who developed DHF and those who did not using a leave-one-out cross-validation method.
For each reconstructed dataset, taking each DHF case in turn, we initially identified all individuals who were in the cohort at the same time as the DHF infection with detectable titres who themselves did not have a DHF infection within a 1-year period. We then randomly selected one of those individuals and used the titre from that day. Once we had selected a matched control for each DHF case, we calculated the receiver operating characteristic (ROC) using leave-one-out cross-validation. To do this, we removed each individual in turn from the dataset (including both the cases and the controls) and recalculated the relationship between mean haemagglutination inhibition titre and DHF infection using all the remaining titre readings. We then predicted the probability that the held-out case had a DHF infection. The ROC was calculated using these probabilities across individuals. We present the mean ROC from across 100 reconstructed datasets. Clustering of infections by school. For additional model validation, we explore whether augmented infections occurred in the same schools around the same time as observed cases, despite no information on location being provided to the model. Clustering of subclinical infections within schools. To explore the clustering of subclinical data with symptomatic infections in schools, we use the tau-clustering statistic 31, 38 to calculate the odds of observing an subclinical infection (irrespective of serotype and infection parity) within a set time period (t 1 , t 2 ) of a symptomatic infection within the same school relative to the odds of observing a subclinical infection in a different school within the same time window.
where: where N symp and N asymp are the number of symptomatic and subclinical infections within any model iteration, I is an indicator variable, sch ij is equal to 1 if individuals i and j go to the same school and 0 otherwise, s ij is the time between infections. We varied the time window between 0-90, 90-180 days and greater than 180 days. Clustering of serotypes within schools. We explore whether the augmented serotypes that were assigned to subclinical primary infections (serotypes could not reliably be assigned in subsequent infections because of cross-reactions) were consistent with the serotypes of the symptomatic infections of individuals within the same school for different periods of time.
For augmented primary infections that are consistently of the same serotype (defined as >50% of augmented datasets having a primary infection in the same individual caused by the same serotype in the same six-month time window), we calculated the odds that an augmented primary infection that occurs in the same school and within a fixed time window of a PCR-confirmed case is of the same serotype relative to the odds that an augmented primary infection that occurs within the same time window in a different school is of the same serotype. where: where ser ij is equal to 1 if i and j go to the same school and 0 otherwise. We varied the time window between 0-90 days, 90-180 days and greater than 180 days. Uncertainty. To incorporate sampling uncertainty into our estimates, for each model iteration, we randomly selected all infection events with replacement before calculating the tau estimates. The 95% confidence intervals were calculated from the 2.5% and the 97.5% quantiles of the resulting distribution across all model iterations. Different approaches to identify infections using simple cutoff points. To assess the sensitivity and specificity of the current approach to identify infections based on titre differences across two blood draws, we simulated titre trajectories in which infections did and did not take place.
Extended Data Fig. 2 | Variability in titre responses and measurement error and bias by serotype. a, Variability in titre responses. Violin plots showing median (black square), 25% and 75% quantiles (thick black line) and 95% distribution (in grey) of net titre increases at different time points after infection (n = 1,420). b, Estimated underlying differences across serotypes in the measurement of antibody levels by haemagglutination inhibition assay over that attributable to infection (DENV1 is reference (Ref.)) with 95% credible intervals (fitted to data from 140,612 titre measurements). c, Mean estimated error in the haemagglutination inhibition assay estimated with 95% credible intervals using our model results (grey) and empirically derived (blue) results from 795 repeated measurements on the same serum compared to the values from previously empirically derived estimates 12 for PRNTs (blue). 
Extended Data Fig. 8 | ROC for infection detection using different testing protocols. The ROC for different assay approaches and time between blood draws calculated from 100,000 simulated titre responses. a, Single serotype assay-when haemagglutination inhibition tests are conducted for only a single serotype at two time points. b, Haemagglutination inhibition tests conducted against all four serotypes.
Infections are considered to occur when the ratio of any of the four titres at time point 2 versus time point 1 is greater than the threshold value. c, Haemagglutination inhibition tests conducted against all four serotypes. Infections are considered to occur when the ratio of the mean of the four titres at time point 2 versus the mean at time point 1 is greater than the threshold value. Corresponding author(s): Henrik Salje Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined.
The paper represents an analysis of data coming out of a school based cohort that ran in Thailand 1998-2002. There were 3,451 participants. A rolling recruitment approach was used to keep an average sample size of around 2,000 as children aged out of the cohort. The model used in this paper are based on antibody titers to all four serotypes from blood draws taken on average every 91 days from these participants (143,548 titer readings). As the paper represents a reanalysis of existing data, there were no sample size calculations in determining the cohort size. We used all available data in the analysis.
Data exclusions
Describe any data exclusions.
No data were excluded
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Model parameter estimates were calculated using an MCMC approach that incorporates uncertainty estimates. We used a bootstrap approach for the relationship between titer and risk of infection/disease to incorporate sampling uncertainty. In order to ensure that our framework could reliably estimate the parameters, we built a simulated dataset with known parameters and then re-estimated them with our model. We were able to obtain the correct parameter values. This analysis is presented in the paper.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Not an experimental design so there were no groups
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Not an experimental design so no blinding Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons Test values indicating whether an effect is present Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Analysis was conducted using c++ and R For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
